NICE Recommends Lynparza Tablets for Relapsed, BRCA-mutated Advanced Ovarian Cancers
News
After an initial rejection due to cost-effectiveness concerns, the U.K.’s National Institute of Health and Care Excellence (NICE) has reversed its decision and is expanding the use of Lynparza (olaparib) tablets ... Read more